Erectile dysfunction
▶BY MOUTH
▶Adult: Initially 100 mg, to be taken approximately
15–30 minutes before sexual activity, then adjusted
according to response to 50–200 mg (max. per dose
200 mg), to be taken as a single dose as needed;
maximum 1 dose per day
Erectile dysfunction in patients on alpha-blocker therapy
▶BY MOUTH
▶Adult: Initially 50 mg, to be taken approximately
15–30 minutes before sexual activity, then adjusted
according to response to 50–200 mg (max. per dose
200 mg), to be taken as a single dose as needed;
maximum 1 dose per day
PDF page 880
DUE TO INTERACTIONS
▶Manufacturer advises max. 100 mg once every 48 hours
with concurrent use of moderate inhibitors of CYP3A4.
PDF page 880
Avoid if systolic blood pressure
below 90 mmHg (no information available). blood pressure
>170/100 mmHg. hereditary degenerative retinal
disorders. history of non-arteritic anterior ischaemic optic
neuropathy. life-threatening arrhythmia in previous
6 months. mild to severe heart failure. patients in whom
vasodilation or sexual activity are inadvisable. recent
history of myocardial infarction. recent history of stroke.
recent unstable angina
PDF page 880
Active peptic ulceration. anatomical
deformation of the penis (e.g. angulation, cavernosal
fibrosis, Peyronie’s disease). bleeding disorders.
cardiovascular disease. left ventricular outflow
obstruction. predisposition to priapism (e.g. in sickle-cell
disease, multiple myeloma, or leukaemia)
CAUTIONS, FURTHER INFORMATION
▶Elderly For phosphodiesterase type-5 inhibitors,
prescription potentially inappropriate (STOPP criteria) in
severe heart failure characterised by hypotension i.e.
systolic blood pressure less than 90 mmHg, or concurrent
nitrate therapy for angina (risk of cardiovascular collapse).
See also Prescribing in the elderly p. 33.
PDF page 880
Scottish Medicines Consortium (SMC) decisions
SMC No. 980/14
The Scottish Medicines Consortium has advised (September
2015) that avanafil (Spedra ®) is not recommended for use
within NHS Scotland, for treatment of erectile dysfunction
in men as the clinical and economic analysis presented
was not sufficiently robust.
All Wales Medicines Strategy Group (AWMSG) decisions
AWMSG No. 1261
The All Wales Medicines Strategy Group has advised (July
2015) that avanafil (Spedra ®) is recommended as an option
for use within NHS Wales for the treatment of erectile
dysfunction in men.
NHS restrictions Spedra ® is not prescribable in NHS
primary care for the treatment of erectile dysfunction
except in men who meet the criteria listed in part XVIIIB of
the Drug Tariff. The prescription must be endorsed ’SLS’.
For more information see Prices in the BNF, under How to
use the BNF.
PDF page 881